Table of Contents
Chemotherapy Research and Practice
Volume 2012, Article ID 901320, 10 pages
http://dx.doi.org/10.1155/2012/901320
Review Article

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

1Aerodigestive and Thoracic Tumor Program, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
3UCSF School of Medicine, University of California San Francisco, San Francisco, CA 94115, USA

Received 14 May 2012; Accepted 22 July 2012

Academic Editor: Basil El-Rayes

Copyright © 2012 Scott A. Kono et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Seigel, E. Ward, O. Brawley, and A. Jemal, “The Impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” CA Cancer Journal for Clinicians, vol. 61, no. 4, pp. 212–236.
  2. N. Howlander, A. M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, National Cancer Institute, Bethesda, Md, USA, 2008.
  3. R. I. Haddad and D. M. Shin, “Recent advances in head and neck cancer,” New England Journal of Medicine, vol. 359, no. 11, pp. 1096–1154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. D'Souza, A. R. Kreimer, R. Viscidi et al., “Case-control study of human papillomavirus and oropharyngeal cancer,” New England Journal of Medicine, vol. 356, no. 19, pp. 1944–1956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. K. Ang, J. Harris, R. Wheeler et al., “Human papillomavirus and survival of patients with oropharyngeal cancer,” New England Journal of Medicine, vol. 363, no. 1, pp. 24–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. http://seer.cancer.gov/fastfacts/selections.php?#Output.
  7. M. Gasco and T. Crook, “The p53 network in head and neck cancer,” Oral Oncology, vol. 39, no. 3, pp. 222–231, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Grandis, M. F. Melhem, W. E. Gooding et al., “Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 824–832, 1998. View at Google Scholar · View at Scopus
  9. J. W. Lee, Y. H. Soung, S. Y. Kim et al., “Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 11, no. 8, pp. 2879–2882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Chung, K. Ely, L. McGavran et al., “Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4170–4176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Wheeler, D. R. Siwak, and R. Chai, “Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma,” Clinical Cancer Research, vol. 18, no. 8, pp. 2278–2289, 2012. View at Google Scholar
  13. C. Fakhry, W. H. Westra, S. Li et al., “Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 261–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Rischin, R. Young, and R. Fisher, “Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial,” Journal of Clinical Oncology, vol. 27, no. 15s, abstract 6004, 2009. View at Google Scholar
  15. B. Kumar, K. G. Cordell, J. S. Lee et al., “EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3128–3137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Brockstein, D. J. Haraf, A. W. Rademaker et al., “Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience,” Annals of Oncology, vol. 15, no. 8, pp. 1179–1186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. Pignon, J. Bourhis, C. Domenge, and L. Designé, “Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data,” Lancet, vol. 355, no. 9208, pp. 949–955, 2000. View at Google Scholar · View at Scopus
  18. M. R. Posner, D. M. Hershock, C. R. Blajman et al., “Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer,” New England Journal of Medicine, vol. 357, no. 17, pp. 1705–1715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Kies, F. C. Holsinger, J. J. Lee et al., “Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 8–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. J. Wanebo, M. S. Ghebremichael, and B. Burtness, “Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG, E2303),” Journal of Clinical Oncology, vol. 28, no. 15s, abstract 5513, 2010. View at Google Scholar
  21. E. Cohen and M. Kocherginsky, “DeCIDE: a Phase III randomized trial of docetaxel (D), cisplatin, 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN),” Journal of Clinical Oncology, vol. 30, supplement, abstract 5500, 2012. View at Google Scholar
  22. R. Haddad, G. Rabinowits, R. B. Tishler et al., “The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC),” Journal of Clinical Oncology, vol. 30, supplement, abstract 5501, 2012. View at Google Scholar
  23. P. Blanchard, B. Baujat, V. Holostenco et al., “Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site,” Radiotherapy and Oncology, vol. 100, no. 1, pp. 30–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. D. J. Adelstein, Y. Li, G. L. Adams et al., “An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 92–98, 2003. View at Google Scholar · View at Scopus
  25. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Rademaker-Lakhai, M. Crul, L. Zuur et al., “Relationship between cisplatin administration and the development of ototoxicity,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 918–924, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Liang, K. K. Ang, L. Milas, N. Hunter, and Z. Fan, “The epidermal growth factor receptor mediates radioresistance,” International Journal of Radiation Oncology Biology Physics, vol. 57, no. 1, pp. 246–254, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Bonner, N. J. Maihle, B. R. Folven, T. J. H. Christianson, and K. Spain, “The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities,” International Journal of Radiation Oncology Biology Physics, vol. 29, no. 2, pp. 243–247, 1994. View at Google Scholar · View at Scopus
  29. H. Lu, K. Liang, and Y. Lu, “The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α,” Cancer Letters, vol. 322, no. 1, pp. 78–85, 2012. View at Google Scholar
  30. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival,” The Lancet Oncology, vol. 11, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Fan, J. Baselga, H. Masui, and J. Mendelsohn, “Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts,” Cancer Research, vol. 53, no. 18, pp. 4637–4642, 1993. View at Google Scholar · View at Scopus
  32. K. K. Ang, Q. E. Zhang, and D. I. Rosenthal, “A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC),” Journal of Clinical Oncology, vol. 29, no. 15s, abstract 5500, 2011. View at Google Scholar
  33. R. J. Young, D. Rischin, R. Fisher et al., “Relationship between epidermal growth factor receptor status, p16 INK4A, and outcome in head and neck squamous cell carcinoma,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 6, pp. 1230–1237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Marur and A. A. Forastiere, “Head and neck cancer: changing epidemiology, diagnosis, and treatment,” Mayo Clinic Proceedings, vol. 83, no. 4, pp. 489–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere, “Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8646–8654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. J. B. Vermorken, J. Trigo, R. Hitt et al., “Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2171–2177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Licitra, R. Mesia, F. Rivera et al., “Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study,” Annals of Oncology, vol. 22, no. 5, pp. 1078–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. D. J. Jonker, C. J. O'Callaghan, C. S. Karapetis et al., “Cetuximab for the treatment of colorectal cancer,” New England Journal of Medicine, vol. 357, no. 20, pp. 2040–2048, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Kuenen, P. O. Witteveen, R. Ruijter et al., “A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies,” Clinical Cancer Research, vol. 16, no. 6, pp. 1915–1923, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Van Lammerts Bueren, W. K. Bleeker, H. O. Bøgh et al., “Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action,” Cancer Research, vol. 66, no. 15, pp. 7630–7638, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. W. K. Bleeker, J. J. Lammerts Van Bueren, H. H. Van Ojik et al., “Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy,” Journal of Immunology, vol. 173, no. 7, pp. 4699–4707, 2004. View at Google Scholar · View at Scopus
  43. L. Bastholt, L. Specht, K. Jensen et al., “Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck,” Radiotherapy and Oncology, vol. 85, no. 1, pp. 24–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. J. P. Machiels, S. Subramanian, A. Ruzsa et al., “Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 4, pp. 333–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. López-Albaitero and R. L. Ferris, “Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer,” Archives of Otolaryngology, vol. 133, no. 12, pp. 1277–1281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Schneider-Merck, J. J. Van Lammerts Bueren, S. Berger et al., “Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage,” Journal of Immunology, vol. 184, no. 1, pp. 512–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. K. A. Foon, X. D. Yang, L. M. Weiner et al., “Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 984–990, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. T. J. Kruser, E. Armstrong, and S. Huang, “Panitumumab, a fully human anti-EGFR monoclonal antibody, augments radiation response in xenograft models of upper aerodigestive tract cancers,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 3, pp. S615–S616, 2007. View at Google Scholar
  49. L. J. Wirth, A. M. Allen, M. R. Posner et al., “Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck,” Annals of Oncology, vol. 21, no. 2, pp. 342–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. B. Vermorken, J. Stohlmacher, and I. Davidenko, “Primary efficacy and safety results of SPECTRUM, a Phase III trial in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) receiving chemotherapy with or without Panitumumab,” Annals of Oncology, vol. 21, no. 8, supplement, article LBA26, 2010. View at Google Scholar
  51. Y. Akashi, I. Okamoto, T. Iwasa et al., “Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status,” British Journal of Cancer, vol. 98, no. 4, pp. 749–755, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Crombet, L. Torres, E. Neninger et al., “Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer,” Journal of Immunotherapy, vol. 26, no. 2, pp. 139–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Crombet, M. Osorio, T. Cruz et al., “Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1646–1654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. M. O. Rodriguez, T. C. Rivero, B. R. del Castillo et al., “Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck,” Cancer Biology & Therapy, vol. 9, no. 5, pp. 343–349, 2010. View at Google Scholar
  55. D. L. Wheeler, S. Huang, T. J. Kruser et al., “Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members,” Oncogene, vol. 27, no. 28, pp. 3944–3956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. J. C. Sok, F. M. Coppelli, S. M. Thomas et al., “Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting,” Clinical Cancer Research, vol. 12, no. 17, pp. 5064–5073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Tinhofer, K. Klinghammer, W. Weichert et al., “Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab - Docetaxel treatment,” Clinical Cancer Research, vol. 17, no. 15, pp. 5197–5204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. T. G. Johns, E. Stockert, G. Ritter et al., “Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene,” International Journal of Cancer, vol. 98, no. 3, pp. 398–408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Mishima, T. G. Johns, R. B. Luwor et al., “Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor,” Cancer Research, vol. 61, no. 14, pp. 5349–5354, 2001. View at Google Scholar · View at Scopus
  60. R. B. Luwor, T. G. Johns, C. Murone et al., “Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR,” Cancer Research, vol. 61, no. 14, pp. 5355–5361, 2001. View at Google Scholar · View at Scopus
  61. T. G. Johns, R. B. Luwor, C. Murone et al., “Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15871–15876, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. A. M. Scott, F. T. Lee, N. Tebbutt et al., “A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors,” Proceedings of the National Academy of Sciences of the USA, vol. 104, pp. 4071–4076, 2007. View at Google Scholar
  63. A. Viloria-Petit, T. Crombet, S. Jothy et al., “Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis,” Cancer Research, vol. 61, no. 13, pp. 5090–5101, 2001. View at Google Scholar · View at Scopus
  64. Y. Lu, X. Li, K. Liang et al., “Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab,” Cancer Research, vol. 67, no. 17, pp. 8240–8247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. M. E. Marshall, T. K. Hinz, S. A. Kono et al., “Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells,” Clinical Cancer Research, vol. 17, no. 15, pp. 5016–5025, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Greenhalgh, A. Bagust, A. Boland et al., “Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck,” Health Technology Assessment, vol. 13, pp. 49–54, 2009. View at Google Scholar · View at Scopus